Mar 24, 2026 03:59AM Piper Sandler Starts Relmada Therapeutics Inc (RLMD) at Overweight

Mar 20, 2026 06:37AM Relmada Therapeutics Inc (RLMD) PT Raised to $19 at Mizuho

Mar 19, 2026 04:10PM Relmada Therapeutics (RLMD) Misses Q4 EPS by 10c

Mar 13, 2026 02:49PM Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD): pullback 'a buying opprotunity'

Mar 9, 2026 08:31AM Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD) following "home run with the 12-month data"

Mar 2, 2026 06:05AM Lucid Capital Markets Starts Relmada Therapeutics Inc (RLMD) at Buy

Jan 23, 2026 06:20AM Leerink Partners Upgrades Relmada Therapeutics Inc (RLMD) to Outperform

Jan 12, 2026 07:02AM Relmada gets FDA alignment on NDV-01 bladder cancer trial designs

Dec 23, 2025 10:00AM Why Jefferies sees these stocks as standout biotech plays in 2026

Dec 22, 2025 12:49AM Jefferies Starts Relmada Therapeutics Inc (RLMD) at Buy

Dec 21, 2025 08:00PM Here's the list of top biotech stocks to own for 2026

Nov 19, 2025 04:02AM Mizuho Upgrades Relmada Therapeutics Inc (RLMD) to Outperform

Nov 13, 2025 04:31PM Relmada Therapeutics (RLMD) Tops Q3 EPS by 15c

Sep 16, 2025 11:20AM Sidoti Events, LLC's Virtual September Small-Cap Conference

Sep 16, 2025 11:20AM Sidoti Events, LLC's Virtual September Small-Cap Conference

Sep 16, 2025 11:20AM Sidoti Events, LLC's Virtual September Small-Cap Conference

Sep 16, 2025 11:20AM Sidoti Events, LLC's Virtual September Small-Cap Conference

Sep 10, 2025 07:15AM Relmada outlines Phase 3 trial plans for bladder cancer drug NDV-01

Aug 7, 2025 04:22PM Relmada Therapeutics (RLMD) Tops Q2 EPS by 10c

Jul 15, 2025 08:02AM Relmada Therapeutics names Yair Lotan to chair clinical advisory board

May 12, 2025 04:04PM Relmada Therapeutics (RLMD) Misses Q1 EPS by 21c

Apr 28, 2025 01:39PM Relmada Therapeutics (RLMD) Presents Positive Initial Phase 2 NDV-01 Data

Mar 26, 2025 05:59AM Mizuho Reiterates Neutral Rating on Relmada Therapeutics Inc (RLMD)

Mar 25, 2025 07:32AM Relmada Therapeutics (RLMD) Licenses NDV-01 from Trigone Pharma

Feb 6, 2025 03:18PM Relmada Therapeutics Inc (RLMD) Sepranolone deal could Have 'blockbuster potential' - Mizuho

Feb 6, 2025 07:30AM Relmada Therapeutics (RLMD) Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

Dec 9, 2024 07:31AM Relmada Therapeutics (RLMD) to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

Dec 5, 2024 02:59AM Mizuho Downgrades Relmada Therapeutics Inc (RLMD) to Neutral

Dec 4, 2024 12:15PM Leerink Partners Downgrades Relmada Therapeutics Inc (RLMD) to Market Perform

Dec 4, 2024 07:30AM Relmada Therapeutics (RLMD) Reports That Data Monitoring Committee Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficac

Nov 14, 2024 07:31AM Relmada Therapeutics (RLMD) Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

Nov 7, 2024 04:34PM Relmada Therapeutics (RLMD) Misses Q3 EPS by 4c

Sep 17, 2024 04:01AM Jefferies Upgrades Relmada Therapeutics Inc (RLMD) to Buy

Sep 12, 2024 07:54AM Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD)

Aug 30, 2024 04:25PM Relmada Therapeutics (RLMD) Files $250M Mixed Shelf

Aug 7, 2024 04:22PM Relmada Therapeutics (RLMD) Tops Q2 EPS by 24c

Jun 18, 2024 08:31AM Relmada Therapeutics (RLMD) Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017